Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors

Protein Science

Volumn 21, Issue 3, 2012, Pages 339-350

  Tie, Yunfeng ^a   Wang, Yuan Fang ^a   Boross, Peter I ^b   Chiu, Ting Yi ^a   Ghosh, Arun K ^c   Tozser, Jozsef ^b   Louis, John M ^d   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c PURDUE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antiviral inhibitors; Aspartic protease; Drug resistance; HIV AIDS; Molecular recognition

Indexed keywords

AMPRENAVIR; ANILINE; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS 2 PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; MUTATION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BINDING SITES; CARBAMATES; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; KINETICS; SAQUINAVIR; SULFONAMIDES;

EID: 84863115391     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2019     Document Type: Article

References (48)

1. AIDS at 30: Nations at the crossroads (2011) Geneva, Switzerland. http://www.unaids.org.
2. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI (2011) Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011:463704.
3. Menendez-Arias L, Tozser J (2008) HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci 29:42-49.
4. Bock PJ, Markovitz DM (2001) Infection with HIV-2. AIDS 15 (Suppl 5):S35-S45. (Pubitemid 34019160)
5. Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, Damond F, Brun-Vezinet F, Desenclos JC, Semaille C (2007) Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 21:2351-2353. (Pubitemid 350287466)
6. Maniar JK, Damond F, Kamath RR, Mandalia S, Surjushe A (2006) Antiretroviral drug-resistant HIV-2 infection-a new therapeutic dilemma. Int J STD AIDS 17:781-782. (Pubitemid 44703967)
7. Louis JM, Weber IT, Tozser J, Clore GM, Gronenborn AM (2000) HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol 49:111-146.
8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235-242. (Pubitemid 30047768)
9. Brower ET, Bacha UM, Kawasaki Y, Freire E (2008) Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 71:298-305. (Pubitemid 351347797)
10. Gustchina A, Weber IT (1991) Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10:325-339.
11. Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC (1994) Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem 269: 26344-26348.
12. Kovalevsky AY, Louis JM, Aniana A, Ghosh AK, Weber IT (2008) Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV- 2 protease. J Mol Biol 384:178-192.
13. Tozser J, Weber IT, Gustchina A, Blaha I, Copeland TD, Louis JM, Oroszlan S (1992) Kinetic and modeling studies of S3-S30 subsites of HIV proteinases. Biochemistry 31:4793-4800.
14. Bagossi P, Sperka T, Feher A, Kadas J, Zahuczky G, Miklossy G, Boross P, Tozser J (2005) Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J Virol 79: 4213-4218. (Pubitemid 40388359)
15. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2010) Update of the drug resistance mutations in HIV- 1: December 2010. Top HIV Med 18:156-163.
16. Hoog SS, Towler EM, Zhao B, Doyle ML, Debouck C, Abdel-Meguid SS (1996) Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry 35: 10279-10286. (Pubitemid 26277286)
17. Swairjo MA, Towler EM, Debouck C, Abdel-Meguid SS (1998) Structural role of the 30's loop in determiningthe ligand specificity of the human immunodeficiency virus protease. Biochemistry 37:10928-10936. (Pubitemid 28368916)
18. Shen CH, Wang YF, Kovalevsky AY, Harrison RW, Weber IT (2010) Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J 277:3699-3714.
19. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, Campa P, Matheron S, Chene G, Brun- Vezinet F, Descamps D (2008) In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 52:1545-1548.
20. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W (2004) Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9:57-65. (Pubitemid 38313948)
21. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V (2006) Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 57:709-713.
22. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA (2007) Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 51:604-610. (Pubitemid 46185279)
23. Eizert H, Bander P, Bagossi P, Sperka T, Miklossy G, Boross P, Weber IT, Tozser J (2008) Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. J Virol 82:10111-10117.
24. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338:341-352. (Pubitemid 38447090)
25. Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2006) Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 363:161-173. (Pubitemid 44437563)
26. Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT (2007) Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins 67:232-242. (Pubitemid 46340142)
27. Louis JM, Zhang Y, Sayer JM, Wang YF, Harrison RW, Weber IT (2011) The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts. Biochemistry 50:4786-95.
28. Sarkhel S, Desiraju GR (2004) N-H⋯O, O-H⋯O, and C-H⋯O hydrogen bonds in protein-ligand complexes: strong and weak interactions in molecular recognition. Proteins 54:247-259. (Pubitemid 38084066)
29. Sayer JM, Agniswamy J, Weber IT, Louis JM (2010) Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance. Protein Sci 19:2055-2072.
30. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38:3919-3925. (Pubitemid 32233182)
31. Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, Polikarpov I (2007) Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J Mol Biol 369:1029-1040. (Pubitemid 46754060)
32. Louis JM, Clore GM, Gronenborn AM (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol 6:868-875. (Pubitemid 29415180)
33. Mahalingam B, Louis JM, Hung J, Harrison RW, Weber IT (2001) Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43:455-464. (Pubitemid 32476440)
34. Louis JM, Ishima R, Aniana A, Sayer JM (2009) Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease. Protein Sci 18:2442-2453.
35. Tozser J, Blaha I, Copeland TD, Wondrak EM, Oroszlan S (1991a) Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett 281:77-80.
36. Maibaum J, Rich DH (1988) Inhibition of porcine pepsin by two substrate analogues containing statine: the effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. J Med Chem 31:625-629. (Pubitemid 18070582)
37. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data in oscillation mode. Methods Enzymology 276:307-326. (Pubitemid 27085611)
38. Navaza J (1994) A MoRe: an Automated Package for Molecular Replacement. Acta Crystallogr Sect A 50:157-163.
39. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. Acta Cryst D 50:760-763.
40. Potterton E, Briggs P, Turkenburg M, Dodson EA (2003) Graphical user interface to the CCP4 program suite. Acta Cryst D 59:1131-1137. (Pubitemid 36872348)
41. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximumlikelihood method. Acta Crystallogr D 53:240-255. (Pubitemid 27235885)
42. Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr A 64:112-122.
43. Jones TA (2004) Interactive electron-density map interpretation: from INTER to O. Acta Crystallogr D Biol Crystallogr 60:2115-2125.
44. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
45. Esnouf RM (1997) An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol Graph Model 15:132-134.
46. Esnouf RM (1999) Further additions to MolScript version 1.4, including reading and contouring of electrondensity maps. Acta Cryst D55:938-940.
47. DeLano WL (2002) The PyMOL Molecular Graphics System. http://www.pymol.org.
48. Tozser J, Gustchina A, Weber IT, Blaha I, Wondrak EM, Oroszlan S (1991b) Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett 279:356-360.